secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2024-12-31T23:59:59+00:00
Accession:  0001193125-24-287073
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 5.03, 2.01, 3.02, 3.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Therapeutics acquires Nova Pharmaceuticals in merger; issues Series B Preferred and closes $2.885M PIPE
--------------------------------------------------------------------------------

- Acquisition closed Dec 30; Galera issued 119,318 shares of Series B Non-Voting Convertible Preferred (1,000-to-1 conversion).
- Raised $2.885M via private placement of 44,111,260 common shares and pre-funded warrants.
- Three directors resigned (Powell, West, Cunningham); Nancy Chang and Michael Friedman appointed as Class I directors.
- Board reduced from six to five; stockholders to vote on Series B conversion and reverse split within 12-18 months.
- 90-day lock-up on shares from merger for certain securityholders and directors/officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/0001193125-24-287073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312524287073/d899535d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-287073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer